A Three-Point, Low-Dose, Artery-Targeted Botulinum Toxin Treatment for Chronic Migraine: A Randomized, Double-Blind, Contralateral-Controlled Trial
- 25 August 2026
- journal article
- research article
- Published by Springer Nature in Aesthetic Plastic Surgery
- Vol. 50 (19) , 8039-8047
Abstract
Introduction Migraine is a prevalent neurovascular disorder with complex neural and vascular mechanisms. Botulinum toxin type A (BoNT-A) is an established preventive treatment for chronic migraine, yet its vascular effects remain unclear. This study investigated whether targeted BoNT-A injections along migraine-related arteries reduce headache intensity and alter vascular diameter. Materials and Methods In this prospective, randomized, double-blind, controlled trial, 23 adults with chronic migraine received BoNT-A injections on one side of the head and saline on the contralateral side. Three injection points were placed along the superficial temporal artery (STA). Ultrasound measurements of the STA (proximal and distal) and supraorbital (SO) arteries were obtained at baseline, 1 h, 2 weeks, and 2 months. Pain intensity was assessed using a 10-point Visual Analogue Scale (VAS). Results Mean VAS scores on the BoNT-A–treated side decreased significantly from 8.7 ± 1.46 at baseline to 2.65 ± 1.15 at 2 months (p < 0.001). No significant vascular diameter changes were detected in the STA or SO arteries between treatment and control sides (p < 0.05). No adverse events were reported. Conclusion Artery-targeted BoNT-A injections produced a significant reduction in migraine pain without measurable arterial dilation, suggesting that therapeutic effects are mediated primarily through neural and neurochemical modulation rather than vascular diameter changes. This low-dose, artery-focused approach may represent a safe, efficient refinement of current migraine injection protocols. Level of Evidence II This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.com/00266.Keywords
This publication has 36 references indexed in Scilit:
- Comparing Phase III Research Evaluating Migraine Prophylaxis Therapy (PREEMPT) and Targeted Approaches for OnabotulinumtoxinA in Chronic Migraine TreatmentPlastic and Reconstructive Surgery - Global Open, 2026
- Botulinum Toxin Vascular Effectiveness: Low or High Doses?Aesthetic Plastic Surgery, 2026
- Vascular Effects of Botulinum Toxin in Human SkinPlastic and Reconstructive Surgery - Global Open, 2025
- Targeted Peripheral Nerve-directed Onabotulinumtoxin A Injection for Effective Long-term Therapy for Migraine HeadachePlastic and Reconstructive Surgery - Global Open, 2017
- Migraine headache trigger site prevalence analysis of 2590 sites in 1010 patientsJournal of Plastic, Reconstructive & Aesthetic Surgery, 2017
- OnabotulinumtoxinA for treatment of chronic migraine: PREEMPT 24-week pooled subgroup analysis of patients who had acute headache medication overuse at baselineJournal of the Neurological Sciences, 2013
- Migraine ChronificationCurrent Neurology and Neuroscience Reports, 2011
- Chronic Migraine: Epidemiology and Disease BurdenCurrent Pain and Headache Reports, 2010
- A Series of Three Sequential, Randomized, Controlled Studies of Repeated Treatments With Botulinum Toxin Type A for Migraine ProphylaxisThe Journal of Pain, 2006
- Botulinum Toxin Type A as a Migraine Preventive TreatmentHeadache: The Journal of Head and Face Pain, 2000